This work is devoted to the study of biocompatibility, cyto- and genotoxicity, mechanism of action and prospects for the use of atranorin, which is an AKT kinase inhibitor, for the treatment of myelodysplastic syndrome. Atra- norin was isolated by preparative flash chromatography; identification was carried out by UV, IR, and NMR spec- troscopy, mass spectrometry, and elemental analysis. Biocompatibility studies included studies of haemocompat- ibility, genotoxicity, antioxidant activity, cytotoxicity against ECV340 and HEK293 cell lines. Computer model- ling of the interaction of atranorin with AKT kinase was carried out using docking followed by molecular dynam- ics of the resulting complexes; the ADMET properties of atranorin were also calculated. Flow cytometry included analysis of the expression level of PD-L1 and TIM-3 in the presence of atranorin on THP-1, Mono-Mac-1 and KG-1 cell lines, as well as human bone marrow cells.